Aurigene Oncology

Bangalore, India· Est. 2001

An Indian clinical-stage biotech company developing innovative small molecule cancer therapies through proprietary discovery and strategic global partnerships.

aurigene.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

An Indian clinical-stage biotech company developing innovative small molecule cancer therapies through proprietary discovery and strategic global partnerships.

OncologyImmunology

Technology Platform

Focuses on novel small molecules for oncology/immunology, with platforms implied for next-gen mechanisms (degraders, bispecifics, ADCs). The A-PROX platform was mentioned for presentation in 2025.

Opportunities

Advancing its proprietary clinical pipeline (e.g., AUR112) to later stages and leveraging its validated discovery engine to form new strategic partnerships with global pharma.

Risk Factors

Clinical trial failures for lead proprietary assets, reliance on partnership revenue, and intense competition in the oncology small molecule space.

Competitive Landscape

Competes with global oncology-focused biotechs and Indian peers like Syngene. Differentiates through its deep experience in integrated drug discovery, focus on novel mechanisms for difficult targets, and capital-efficient India-based R&D model.

More companies in India →